ANTEOTECH LTD — Board/Management Information 2017

Dec 21, 2017

22 December 2017

==> picture [316 x 91] intentionally omitted <==

REQUISITION OF MEETING UNDER SECTION 249D OF CORPORATIONS ACT

In accordance with ASX Listing Rule 3.17A, Anteo Diagnostics Ltd (ASX: ADO) (“ Anteo” or “ Company ”) advises that on 21 December 2017 it received notice under section 249D of the Corporations Act 2001 (Cth), from First Cape Management Pty. Limited and Austcorp No. 190 Pty. Limited requesting the directors of Anteo to call and arrange to hold a meeting of the Company for the purpose of considering the following resolutions:

1. That, pursuant to section 203D of the Corporations Act, Mr John Hurrell be removed as a director of the Company effective immediately on the passing of this resolution and that the Company seek an appropriately qualified person as a replacement director.

2. That, pursuant to section 203D of the Corporations Act, Mr Rolf Sickman be removed as a director of the Company effective immediately on the passing of this resolution.

The Company is seeking advice as to its position and will keep shareholders informed of all material developments in relation to the requisition.

Julien Mcinally Company Secretary

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

For more information, please visit www.anteodx.com

==> picture [118 x 93] intentionally omitted <==

==> picture [268 x 55] intentionally omitted <==